Your session is about to expire
← Back to Search
Retinal Prosthesis
The Perceptual Experience of Argus II Users
N/A
Waitlist Available
Led By Michael Beyeler, PhD
Research Sponsored by University of California, Santa Barbara
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year
Awards & highlights
No Placebo-Only Group
Summary
This trial aims to improve the Argus II device, which helps people with severe vision loss see by sending electrical signals to their eyes. The study focuses on patients with retinal diseases and seeks to make their vision clearer by developing better signal-sending methods. The Argus II device was developed to restore some vision to patients blind due to specific retinal conditions and has been tested for many years.
Eligible Conditions
- Retinitis Pigmentosa
- Blindness
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion, an average of 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Pattern discrimination accuracy
Phosphene brightness relative to reference stimulus
Phosphene shape
+1 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Predicting the perceptual experience of retinal prosthesis patientsExperimental Treatment1 Intervention
This intervention will assess the effect of different stimulation strategies on the perceptual experience of retinal prosthesis patients. We will produce visual percepts in patients either by directly stimulating electrodes (using FDA-approved pulse trains) or by asking them to view a computer or projector screen and using standard FDA-approved stimulation protocols (as is standardly used for their devices) to convert the computer or projector screen image into pulse trains on their electrodes. Existing blind users of the Argus II will be recruited for this study. Performance of Argus II users will be compared to performance of sighted subjects viewing a prosthetic vision simulation in virtual reality.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Argus II
2022
N/A
~70
Find a Location
Who is running the clinical trial?
University of MinnesotaOTHER
1,439 Previous Clinical Trials
1,621,888 Total Patients Enrolled
1 Trials studying Retinitis Pigmentosa
438 Patients Enrolled for Retinitis Pigmentosa
National Eye Institute (NEI)NIH
558 Previous Clinical Trials
1,408,401 Total Patients Enrolled
24 Trials studying Retinitis Pigmentosa
14,488 Patients Enrolled for Retinitis Pigmentosa
University of California, Santa BarbaraLead Sponsor
30 Previous Clinical Trials
2,985 Total Patients Enrolled
Johns Hopkins UniversityOTHER
2,339 Previous Clinical Trials
14,881,701 Total Patients Enrolled
9 Trials studying Retinitis Pigmentosa
834 Patients Enrolled for Retinitis Pigmentosa
University of MichiganOTHER
1,863 Previous Clinical Trials
6,441,503 Total Patients Enrolled
3 Trials studying Retinitis Pigmentosa
466 Patients Enrolled for Retinitis Pigmentosa
Michael Beyeler, PhDPrincipal InvestigatorUniversity of California, Santa Barbara
1 Previous Clinical Trials
10 Total Patients Enrolled